Disclosed herein is a composition comprising a biofilm degrading protease, a disulphide bond breaking agent and an antibiotic, as well as a method for debriding biofilm (e.g. on an implant) in a patient's body. The method comprises contacting the biofilm with a combination of a biofilm degrading protease and disulphide bond breaking agent.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of the hydrophobic polymer to the hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200.

The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.

The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

The present invention relates to methods for the enhancement and stabilisation of the proteolytic activity of proteases, methods for producing compositions comprising proteases with proteolytic activity that has been enhanced and stabilised, compositions comprising proteases with proteolytic activity that has been enhanced and stabilised obtained or obtainable by the aforementioned methods, use of such compositions in the manufacture of medicaments and cosmetics, the use of such compositions in the treatment of diseases and disorders including wounds, and in cosmetic applications, and associated kits.

The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.

Compositions containing bromelain are disclosed for use as topical therapeutic agents to restore healthy skin, and for immediate and extended relief from itching and irritation associated with contact dermatitis, insect bites, idiopathic itch, chronic itch, hives, psoriasis, seborrhea, eczema and cracked fingertips, skin abrasions, cuts and minor burns as well as other indications. The compositions include lotions, creams and ointments.

The present disclosure relates to a compound and method of using such compound, preferably in the form of a dietary supplement that, when administered, is capable of treating thyroid disease and various thyroid-related disorders, such as Hashimoto's thyroiditis. The unique combination of the composition is preferably administered orally via acid resistant or enteric-coated capsule, soft gel or tablet. The composition is preferably comprised of at least Catalase, Reduced Glutathione, Acetylated Glutathione, DPP-IV protease enzyme, Pepsin, Bromelain, Pancreatin, Vitamin D, and Selenium. The composition can further comprise a palliative agent, and can be provided in specific dosages or administered in forms besides those listed above.

An oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The invention entails formulating an aqueous oral suspension of bromelain, Blanose sodium carboxymethyl cellulose, citric acid anhydrous, Epikuron 135F lecithin oil and ethylenedinitrilotetraacetic acid, disodium salt dihydrate (“EDTA”).

A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.